Awards and Achievements

USFDA Approved Manufacturing Facility since 1998

Morepen also holds process patents for Montelukast Sodium Amorphous in Global, USA, Canada, Europe & India.

Awards and Achievements

ISO Certified medical devices Manufacturing Facility

ISO 9001:2005 and ISO 13485:2016 certification for medical devices manufacturing facility at Baddi (H.P.). This enables us as one of the largest manufacturers in point-of-care diagnostic devices in India.

Awards and Achievements

Awarded 3 years consecutively by Pharmexcil

Awarded Certificate of Appreciation by Pharmaceuticals export promotion council (Pharmexcil), setup by Ministry of Commerce & Industry, Government of India for 3 consecutive years.

Investor Centre

Revenue Growth: Net revenue increased by 4% to ₹442.71 crore, up from ₹425.00 crore in Q2 FY24.

EBITDA Surge: EBITDA grew by 33%, reaching ₹49.06 crore in Q2 FY25, compared to ₹36.83 crore in Q2 FY24.

Profit After Tax (PAT): PAT surged 64% to ₹34.85 crore for Q2 FY25, up from ₹21.26 crore in the same quarter last year.

Expansion in Medical Devices: The medical devices segment revenue grew by 9.35% YoY, reaching ₹133 crore. With over 13 million glucometers installed, production expansion is underway to meet growing demand.

Pharma Segment Growth: The pharma division saw a 9% revenue increase, with export revenue up by 21%, bolstered by strong performance in Europe (up 60%) and Asia.

Strategic Investment for Future Growth: Morepen raised ₹200 crore via Qualified Institutional Placement (QIP), facilitating capacity expansions across API and medical devices.

Revenue Growth: Net revenue increased by 4% to ₹442.71 crore, up from ₹425.00 crore in Q2 FY24

EBITDA Surge: EBITDA grew by 33%, reaching ₹49.06 crore in Q2 FY25, compared to ₹36.83 crore in Q2 FY24.

Profit After Tax (PAT): PAT surged 64% to ₹34.85 crore for Q2 FY25, up from ₹21.26 crore in the same quarter last year.

Pharma Segment Growth: The pharma division saw a 9% revenue increase, with export revenue up by 21%, bolstered by strong performance in Europe (up 60%) and Asia.

Strategic Investment for Future Growth: Morepen raised ₹200 crore via Qualified Institutional Placement (QIP), facilitating capacity expansions across API and medical devices.

Self-monitor health with Dr.Morepen

"Dr. Morepen’s devices are user-friendly, quick and reliable. With the help of these devices, we may in fact add Health to our DIY lists, instead of depending on others!”

Dr. Morepen’s clear and accurate result

"Dr. Morepen's device provides a clear and accurate result. Keep an instant check on your bp with the help of BP monitor by Dr. Morepen.”

The original burns cream that India trusts.

Burnol a name every household trusts for quick healing of burns and cuts for more than two decades. An effective antiseptic and antibacterial topical ointment.

Quick relief from cold, cough, & flu

Lemolate Gold is a trusted medicine for cold, cough, and flu that provides superior relief without leaving you drowsy.

Sanitizer that protects!

An alcohol-based sanitizer that thoroughly disinfects your hands while keeping them soft and leaves your hands smelling great!

Awards and Achievements

USFDA Approved Manufacturing Facility since 1998

Awards and Achievements

ISO Certified medical devices Manufacturing Facility

Awards and Achievements

Awarded 3 years consecutively by Pharmexcil

Investor Centre

Self-monitor health with Dr.Morepen

Dr. Morepen’s clear and accurate result

The original burns cream that India trusts.

Quick relief from cold, cough, & flu

Sanitizer that protects!

Life@Morepen

BE A PART OF A CULTURE OF JOY AND PERFECTION